Rheumatoid arthritis market

Nature Reviews Drug Discovery volume 8, pages693–694(2009)Cite this article

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

Figure 1: Rheumatoid arthritis (RA) market.

References

  1. 1

    Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).

  2. 2

    Saag, K. G. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59, 762–784 (2008).

  3. 3

    Breedveld, F. C. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26–37 (2006).

  4. 4

    Smolen, J. S. et al. Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702–710 (2006).

  5. 5

    Klareskog, L. et al. Therapeutic effects of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 363, 675–681 (2004).

  6. 6

    Weinblatt, M. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and non-biologic disease-modifying antirheumatic drugs. Arthritis Rheum. 54, 2807–2816 (2006).

  7. 7

    Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009).

  8. 8

    Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).

Download references

Author information

Affiliations

  1. Jeffrey G. Stoll and Uma Yasothan are at IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK. JStoll@us.imshealth.com; UYasothan@de.imshealth.com
    • Jeffrey G. Stoll
    •  & Uma Yasothan
  2. UYasothan@de.imshealth.com
    • Jeffrey G. Stoll
    •  & Uma Yasothan
Authors
  1. Search for Jeffrey G. Stoll in:
  2. Search for Uma Yasothan in:

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Stoll, J., Yasothan, U. Rheumatoid arthritis market. Nat Rev Drug Discov 8, 693–694 (2009) doi:10.1038/nrd2947

Download citation

Further reading